Method for large-scale production of mesenchymal stem cells by utilizing pluripotent stem cells iPS and application
By converting pluripotent stem cell iPS into mesenchymal stem cells and adsorbing on magnetic nanospheres under the induced ferrotrioxide, the problem of inefficient production and application of mesenchymal stem cells in the prior art is solved, and tendon repair is significantly improved Effect.
Patent Information
- Application Number
- CN202411441784.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-10-16
AI Technical Summary
The prior art is difficult to effectively produce and apply mesenchymal stem cells on a large scale, especially in promoting repair of damaged tendons.
By using pluripotent stem cell iPS to convert it into mesenchymal stem cells under the induction of magnetic iron tetroxide and adsorbing it on the obtained magnetic nanospheres, it promotes the directed differentiation and paracrine function of cells and accelerates the three-dimensional culture of cells. and repair of damaged tendons.
The large-scale production and effective application of mesenchymal stem cells has been achieved, the directed differentiation and paracrine function of cells has been improved, and the repair effect of chronic tendon disease has been significantly promoted.
Abstract
Description
Technical Field
[0001] The present invention relates to the field of stem cell technology, and in particular to a method and application of large-scale production of mesenchymal stem cells using pluripotent stem cells (iPS). Background Art
[0002] Stem cells are the original source of cells in the human body and its various tissues. Their most notable biological characteristics are their ability to self-renew and proliferate continuously, as well as their potential for multidirectional differentiation. Stem cells are divided into adult stem cells (somatic stem cells) and embryonic stem cells (ES cells) according to their different sources. Adult stem cells include bone marrow mesenchymal stem cells, pancreatic stem cells, neural stem cells, etc., which exist in adult tissues.
[0003] Mesenchymal stem cells are widely present in connective tissues and organ stroma throughout the body, with the highest content in bone marrow tissue. They can also be isolated from fetal umbilical cord blood, and also exist in placenta, amniotic fluid, umbilical vein subendothelial layer, peripheral blood, liver, fat, muscle, skin and other tissues. Mesenchymal stem cells have high proliferation, self-renewal and multidirectional differentiation potential. Mesenchymal stem cells can not only differentiate into a variety of tissues and cells, but also be easily isolated, cultured, amplified, and easy to introduce and express exogenous genes. They always maintain the potential for multidirectional differentiation during long-term in vitro culture, and their genetic background is quite stable.
[0004] Mesenchymal stem cells were first used in clinical applications in 1995. In 2012, Osiris applied for mesenchymal stem cells to be marketed as a drug and was approved by the Canadian FDA. The clinical application of mesenchymal stem cells has reached a historic height. Mesenchymal stem cells have now replaced placental stem cells and become the preferred seed cells in biomedical research, and are widely used in basic and clinical research on various diseases. Therefore, it is very necessary to provide a method for preparing mesenchymal stem cells, which is also a hot topic in mesenchymal stem cell research. Summary of the invention
[0005] The purpose of the present invention is to propose a method and application of large-scale production of mesenchymal stem cells using pluripotent stem cells iPS, and large-scale production of mesenchymal stem cells using pluripotent stem cells iPS. Under the induction of magnetic ferroferric oxide, pluripotent stem cells iPS are easily transformed into mesenchymal stem cells, affecting the directional differentiation and paracrine function of stem cells, and promoting the repair of damaged tendons.
[0006] The technical solution of the present invention is achieved in this way:
[0007] The present invention provides a method for large-scale production of mesenchymal stem cells using pluripotent stem cells (iPS), comprising the following steps:
[0008] S1. Inoculate the human iPS cell line in a culture dish covered with matrix gel, culture, change the medium every day, subculture once every 6-7 days, and obtain passage cells after 4-6 subcultures;
[0009] S2. The silica nanospheres were added to water, ferric chloride and ferrous chloride were added, and under the protection of an inert gas, aqueous ammonia was added dropwise, and the reaction was heated and stirred to obtain magnetic nanospheres;
[0010] S3. Inoculate the passaged cells into a culture medium, add magnetic nanospheres, stir and mix evenly, and culture to obtain nanospheres that adsorb mesenchymal stem cells.
[0011] As a further improvement of the present invention, the inoculation amount of the human iPS cell line in step S1 is 2-3×10 4 Cells / cm 2 .
[0012] As a further improvement of the present invention, the culture conditions in step S1 are 36-38° C., 5% CO 2 cell culture incubator.
[0013] As a further improvement of the present invention, the culture medium in step S1 is mTeSRTM1 stem cell complete culture medium.
[0014] As a further improvement of the present invention, the average particle size of the silicon dioxide nanospheres in step S2 is 500-700 nm.
[0015] As a further improvement of the present invention, the mass ratio of the silica nanospheres, ferric chloride, ferrous chloride and ammonia water in step S2 is 10:3.24:1.26:2-4.
[0016] As a further improvement of the present invention, the temperature of the heating and stirring reaction in step S2 is 70-80° C. and the time is 3-5 h.
[0017] As a further improvement of the present invention, the inoculation amount in step S3 is 1-2×10 6 cells / mL.
[0018] As a further improvement of the present invention, the culture conditions in step S3 are 36-38° C., 5% CO 2 cell culture incubator, and the culture time is 5-7 days.
[0019] The present invention further protects the use of mesenchymal stem cells produced on a large scale by the above method in the preparation of medicines for repairing chronic tendinopathy.
[0020] The present invention has the following beneficial effects:
[0021] The present invention utilizes pluripotent stem cells iPS to mass produce mesenchymal stem cells. Under the induction of magnetic ferroferric oxide, the pluripotent stem cells iPS are easily transformed into mesenchymal stem cells and adsorbed and fixed on the prepared magnetic nanospheres, which accelerates the transformation from two-dimensional cell culture to three-dimensional cell culture. While promoting the "industrialized" culture of cells, it can also increase the communication connection between cells, further affecting the directional differentiation and paracrine function of stem cells. At the same time, magnetic ferroferric oxide can also release far-infrared rays, further synergistically promoting the repair of damaged tendons. DETAILED DESCRIPTION
[0022] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] Example 1
[0024] This embodiment provides a method for mass production of mesenchymal stem cells using pluripotent stem cells (iPS), comprising the following steps:
[0025] S1. Inoculate human iPS cell lines in a culture dish covered with matrix gel at a seeding volume of 2×10 4 Cells / cm 2 , 36°C, 5% CO2 cell culture incubator, culture medium is mTeSRTM1 stem cell complete medium, change medium every day, subculture once every 6-7 days, and obtain passage cells after 4-6 subcultures;
[0026] S2. 10 g of silica nanospheres with an average particle size of 500 nm were added to water, 3.24 g of ferric chloride and 1.26 g of ferrous chloride were added, 2 g of ammonia was added dropwise under nitrogen protection, heated to 70 ° C, stirred for 3 h, and magnetic nanospheres were obtained;
[0027] S3. The passaged cells were inoculated in mTeSRTM1 stem cell complete medium at a seeding volume of 1×10 6 cells / mL, add 10wt% of magnetic nanospheres of the total mass of the system, stir and mix evenly, and culture at 36°C, 5% CO2 cell culture incubator for 5 days to obtain nanospheres that adsorb mesenchymal stem cells.
[0028] Example 2
[0029] This embodiment provides a method for mass production of mesenchymal stem cells using pluripotent stem cells (iPS), comprising the following steps:
[0030] S1. The human iPS cell line was inoculated in a culture dish covered with matrix gel at a seeding volume of 3×10 4 Cells / cm 2 , 38°C, 5% CO2 cell culture incubator, culture medium is mTeSRTM1 stem cell complete medium, change medium every day, subculture once every 6-7 days, and obtain passage cells after 4-6 subcultures;
[0031] S2. 10 g of silica nanospheres with an average particle size of 700 nm were added to water, 3.24 g of ferric chloride and 1.26 g of ferrous chloride were added, 4 g of ammonia was added dropwise under nitrogen protection, heated to 80 ° C, stirred for 5 h, and magnetic nanospheres were obtained;
[0032] S3. The passaged cells were inoculated in mTeSRTM1 stem cell complete medium at a seeding volume of 2×10 6 cells / mL, add 10wt% of magnetic nanospheres of the total mass of the system, stir and mix evenly, and culture at 38°C, 5% CO2 cell culture incubator for 7 days to obtain nanospheres adsorbing mesenchymal stem cells.
[0033] Example 3
[0034] This embodiment provides a method for mass production of mesenchymal stem cells using pluripotent stem cells (iPS), comprising the following steps:
[0035] S1. The human iPS cell line was inoculated in a culture dish covered with matrix gel at a seeding volume of 2.5×10 4 Cells / cm 2 , 37°C, 5% CO2 cell culture incubator, culture medium is mTeSRTM1 stem cell complete medium, change medium every day, subculture once every 6-7 days, and obtain passage cells after 4-6 subcultures;
[0036] S2. 10 g of silica nanospheres with an average particle size of 600 nm were added to water, 3.24 g of ferric chloride and 1.26 g of ferrous chloride were added, 3 g of ammonia was added dropwise under nitrogen protection, heated to 75 ° C, stirred for 3-5 h, and magnetic nanospheres were obtained;
[0037] S3. The passaged cells were inoculated in mTeSRTM1 stem cell complete medium at a seeding volume of 1.5×10 6 cells / mL, add 10wt% of magnetic nanospheres of the total mass of the system, stir and mix evenly, and culture at 37°C, 5% CO2 cell culture incubator for 6 days to obtain nanospheres adsorbing mesenchymal stem cells.
[0038] Comparative Example 1
[0039] Compared with Example 3, the difference is that step S2 is not performed, and in step S3, the magnetic nanospheres are replaced by an equal amount of silicon dioxide nanospheres.
[0040] Comparative Example 2
[0041] Compared with Example 3, the difference is that steps S2 and S3 are not performed.
[0042] Test Example 1
[0043] A rat tendinopathy model was established using type I collagenase injection. Before modeling, the rats were adaptively raised in cages for 1 week, fed freely, and randomly divided into 7 groups, with 10 rats in each group. Normal group: injected with an equal amount of normal saline; tendinopathy group: established a tendinopathy model using type I collagenase injection; Example 1-3 and Comparative Example 1-2 group: established a tendinopathy model using type I collagenase injection, and injected the corresponding prepared product (50 mg / L). Rats were anesthetized with 3% sodium pentobarbital (1 mL / kg), the Achilles tendon of the right hind limb of SD rats was located, and 50 μL of type I collagenase (2 mg / mL, injected once every 3 days, for a total of 5 times) was injected with a microsyringe. After 2 weeks, the tendinopathy model was successfully established, and then stem cell transplantation treatment was given using a microsyringe, for a total of 1 injection.
[0044] After 4 weeks of treatment, the functional recovery of the rats was detected using a small animal gait analyzer (CatWalk). The rats were adapted to the surrounding environment under light-proof conditions and placed on the small animal gait analyzer runway with pre-set gait parameters. When the rats passed the fixed detection area runway at a constant speed, the gait characteristics of the rats passing through the runway could be detected based on the pressure generated by the rats' limbs. The results are shown in Table 1.
[0045] Table 1
[0046] Group Standing time (s) <![CDATA[Contact area (mm 2 ) <!-- 3 -->]]> Normal group 0.43±0.19 221±14 Model Group 0.25±0.12 134±5 Example 1 0.35±0.14 178±7 Example 2 0.37±0.15 181±9 Example 3 0.38±0.11 184±10 Comparative Example 1 0.30±0.10 167±8 Comparative Example 2 0.28±0.09 159±6
[0047] It can be seen from the above table that the nanospheres adsorbing mesenchymal stem cells prepared in Examples 1-3 of the present invention have a good effect on repairing chronic tendinopathy.
[0048] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for large-scale production of mesenchymal stem cells using pluripotent stem cells (iPS), characterized in that: The following steps are involved: S1. Inoculate the human iPS cell line in a culture dish covered with matrix gel, culture, change the medium every day, subculture once every 6-7 days, and obtain passage cells after 4-6 subcultures; S2. The silica nanospheres were added to water, ferric chloride and ferrous chloride were added, and under the protection of an inert gas, aqueous ammonia was added dropwise, and the reaction was heated and stirred to obtain magnetic nanospheres; S3. Inoculate the passaged cells into a culture medium, add magnetic nanospheres, stir and mix evenly, and culture to obtain nanospheres that adsorb mesenchymal stem cells.
2. The method according to claim 1, characterized in that: The inoculation volume of the human iPS cell line in step S1 is 2-3×10 4 Cells / cm 2 .
3. The method according to claim 1, characterized in that The culture conditions in step S1 are 36-38° C., 5% CO 2 cell culture incubator.
4. The method according to claim 1, characterized in that: The culture medium in step S1 is mTeSRTM1 stem cell complete culture medium.
5. The method according to claim 1, characterized in that The average particle size of the silicon dioxide nanospheres in step S2 is 500-700 nm.
6. The method according to claim 1, characterized in that The mass ratio of the silica nanospheres, ferric chloride, ferrous chloride and ammonia water in step S2 is 10:3.24:1.26:2-4.
7. The method according to claim 1, characterized in that The temperature of the heating and stirring reaction in step S2 is 70-80° C. and the time is 3-5 hours.
8. The method according to claim 1, characterized in that The inoculum size in step S3 is 1-2×10 6 cells / mL.
9. The method according to claim 1, characterized in that: The culture conditions in step S3 are 36-38° C., 5% CO 2 cell culture incubator, and the culture time is 5-7 days.
10. Use of mesenchymal stem cells produced on a large scale by the method according to any one of claims 1 to 9 in the preparation of drugs for repairing chronic tendinopathy.
Citation Information
Patent Citations
Ferroferric oxide superparamagnetic nanoparticle stimulating stem cell for exosome osteogenesis
CN109745341A
Mesenchymal stem cell preparation capable of treating Alzheimer disease and application of mesenchymal stem cell preparation
CN110585241A
Stem cell preparation and preparation method and application thereof
CN112426440A
Preparation and application of magnetic ferroferric oxide nanoparticle-labeled human umbilical cord mesenchymal stem cells for repairing female reproductive system injury
CN118703429A
Stem cell-produced microvesicles for treating tendon pathologies
US20210322482A1
